|
|
 |
|
|
|
 |
| Market Cap | 8.74M | EPS (ttm) | -133.90 |
| P/E | - | EPS this Y | 83.70% |
| Forward P/E | - | EPS next Y | - |
| PEG | - | EPS past 5Y | 22.10% |
| P/S | 0.23 | EPS next 5Y | - |
| P/B | 0.05 | EPS Q/Q | -47.20% |
| Dividend | - | Sales Q/Q | 1.10% |
| Insider Own | 40.50% | Inst Own | 3.30% |
| Insider Trans | 0.00% | Inst Trans | -99.08% |
| Short Float | 0.05% | Earnings | - |
| Analyst Recom | - | Target Price | - |
| Avg Volume | 73.08K | 52W Range | 11.06 - 203.00 |
|
|
|
|
| ShiftPixy, Inc., together with its subsidiaries, provides staffing solutions in the United States. It offers employment administrative services, such as payroll processing, human resources consulting, and workers' compensation administration and coverage. The Company also operates human resources information systems platform to assist in customer acquisition for the onboarding of new clients into the company's closed proprietary operating and processing information system. It primarily serves restaurant and hospitality service industries. The company was incorporated in 2015 and is headquartered in Miami, Florida. |
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Absher Scott W | CEO | Sep 01 | Option Exercise | 195.47 | 8,600,000 | 1,681,000,000 | 8,608,125 | Sep 02 06:38 PM |
|
|
|
 |
| Market Cap | 1.36B | EPS (ttm) | -2.77 |
| P/E | - | EPS this Y | -108.00% |
| Forward P/E | - | EPS next Y | 54.30% |
| PEG | - | EPS past 5Y | - |
| P/S | 4547.20 | EPS next 5Y | - |
| P/B | 5.41 | EPS Q/Q | -139.00% |
| Dividend | - | Sales Q/Q | - |
| Insider Own | 9.90% | Inst Own | 55.70% |
| Insider Trans | -0.80% | Inst Trans | 8.18% |
| Short Float | 8.32% | Earnings | Aug 11/a |
| Analyst Recom | 1.80 | Target Price | 30.75 |
| Avg Volume | 873.85K | 52W Range | 6.51 - 33.41 |
|
|
|
|
| Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts. |
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| ALS Invest 1 B.V. | 10% Owner | Jul 06 | Sale | 20.70 | 60,609 | 1,254,642 | 5,895,280 | Jul 08 06:44 PM | | Cohen Joshua B | Co-Chief Executive Officer | May 05 | Option Exercise | 0.37 | 334,520 | 123,772 | 2,898,585 | May 06 04:05 PM | | Klee Justin B. | Co-Chief Executive Officer | May 05 | Option Exercise | 0.37 | 334,520 | 123,772 | 2,898,585 | May 06 04:05 PM |
|
|
|
 |
| Market Cap | 3.55B | EPS (ttm) | -1.78 |
| P/E | - | EPS this Y | -24.70% |
| Forward P/E | - | EPS next Y | 16.00% |
| PEG | - | EPS past 5Y | - |
| P/S | 8.42 | EPS next 5Y | - |
| P/B | 23.22 | EPS Q/Q | -39.30% |
| Dividend | - | Sales Q/Q | 57.20% |
| Insider Own | 4.80% | Inst Own | 52.80% |
| Insider Trans | -0.25% | Inst Trans | -5.14% |
| Short Float | 18.10% | Earnings | Sep 07/a |
| Analyst Recom | 2.30 | Target Price | 34.36 |
| Avg Volume | 3.03M | 52W Range | 16.19 - 145.79 |
|
|
| Sep-08-22 09:52AM | Asana stock surges on earnings, outlook boost Yahoo Finance Video |
| Sep-08-22 09:41AM | Asana Stock Spikes on Forecast Boost and Share Sale to CEO Barrons.com |
| Sep-08-22 09:08AM | GameStop's Rising, but This Software Stock Is Thursday's Big Winner Motley Fool |
| Sep-08-22 07:44AM | Asana, GameStop, Moderna, Revance, and More Stock Market Movers Thursday Barrons.com |
| Sep-08-22 05:50AM | Asana Stock Spikes on Forecast Boost and Share Sale to CEO Barrons.com |
| Sep-08-22 03:51AM | GameStop, Asana, First Solar Rise Premarket; American Eagle Outfitters Falls Investing.com |
| Sep-07-22 08:16PM | Asana stock rallies more than 20% after beat-and-raise quarter MarketWatch |
| Sep-07-22 05:25PM | Asana, Inc. (ASAN) Reports Q2 Loss, Tops Revenue Estimates Zacks |
| Sep-07-22 04:30PM | Edited Transcript of ASAN.N earnings conference call or presentation 7-Sep-22 8:30pm GMT Thomson Reuters StreetEvents |
| Sep-07-22 04:05PM | Asana Announces Record Second Quarter Fiscal 2023 Revenues Business Wire |
|
| Asana, Inc., together with its subsidiaries, operates a work management platform for individuals, team leads, and executives in the United States and internationally. The company's platform enables teams to orchestrate work from daily tasks to cross-functional strategic initiatives; and manages product launches, marketing campaigns, and organization-wide goal settings. It serves customers in industries, such as technology, retail, education, non-profit, government, healthcare, media, and financial services. The company was formerly known as Smiley Abstractions, Inc. and changed its name to Asana, Inc. in July 2009. Asana, Inc. was incorporated in 2008 and is headquartered in San Francisco, California. |
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Wan Tim M | Chief Financial Officer | Jun 22 | Sale | 18.20 | 3,203 | 58,295 | 609,276 | Jun 24 07:09 PM | | LACEY ELEANOR B | GC, Corporate Secretary | Jun 22 | Sale | 18.20 | 1,249 | 22,732 | 170,629 | Jun 24 06:52 PM | | LACEY ELEANOR B | GC, Corporate Secretary | May 04 | Option Exercise | 4.02 | 4,167 | 16,751 | 169,243 | May 04 07:50 PM | | LACEY ELEANOR B | GC, Corporate Secretary | May 04 | Sale | 29.50 | 4,167 | 122,926 | 165,076 | May 04 07:50 PM | | LACEY ELEANOR B | GC, Corporate Secretary | May 02 | Option Exercise | 4.02 | 4,167 | 16,751 | 169,243 | May 04 07:50 PM |
|
|
| |
 |
| Market Cap | 2.75B | EPS (ttm) | -2.59 |
| P/E | - | EPS this Y | -49.40% |
| Forward P/E | - | EPS next Y | -13.50% |
| PEG | - | EPS past 5Y | - |
| P/S | 1373.08 | EPS next 5Y | - |
| P/B | 3.53 | EPS Q/Q | 66.40% |
| Dividend | - | Sales Q/Q | -50.00% |
| Insider Own | 0.50% | Inst Own | - |
| Insider Trans | -28.05% | Inst Trans | 7.32% |
| Short Float | 17.35% | Earnings | Aug 04/a |
| Analyst Recom | 2.10 | Target Price | 39.00 |
| Avg Volume | 1.08M | 52W Range | 12.65 - 38.15 |
|
|
|
|
| Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of RLY-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. |
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Bergstrom Donald A | President, R&D | Sep 02 | Option Exercise | 4.12 | 4,900 | 20,188 | 94,559 | Sep 02 05:47 PM | | Bergstrom Donald A | President, R&D | Sep 02 | Sale | 25.46 | 4,900 | 124,754 | 89,659 | Sep 02 05:47 PM | | Bergstrom Donald A | President, R&D | Sep 01 | Option Exercise | 4.12 | 8,100 | 33,372 | 97,759 | Sep 01 08:26 PM | | Bergstrom Donald A | President, R&D | Sep 01 | Sale | 23.07 | 8,100 | 186,867 | 89,659 | Sep 01 08:26 PM | | Bergstrom Donald A | President, R&D | Aug 24 | Option Exercise | 4.12 | 15,000 | 61,800 | 104,659 | Aug 25 05:23 PM |
|
|
|
 |
| Market Cap | 2.78B | EPS (ttm) | -1.03 |
| P/E | - | EPS this Y | -26.00% |
| Forward P/E | - | EPS next Y | 72.50% |
| PEG | - | EPS past 5Y | - |
| P/S | 3.58 | EPS next 5Y | - |
| P/B | 1.76 | EPS Q/Q | 13.00% |
| Dividend | - | Sales Q/Q | 30.50% |
| Insider Own | 13.50% | Inst Own | 83.90% |
| Insider Trans | -1.81% | Inst Trans | 1.26% |
| Short Float | 2.69% | Earnings | Aug 09/a |
| Analyst Recom | 2.30 | Target Price | 8.80 |
| Avg Volume | 665.68K | 52W Range | 4.77 - 16.50 |
|
|
|
|
| LifeStance Health Group, Inc., through its subsidiaries, provides outpatient mental health services. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy. It treats a range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder. In addition, the company operates outpatient mental health platform as well as offers patients care virtually through its online delivery platform or in-person at its centers in 32 states. It serves children, adolescents, adults, and geriatrics. LifeStance Health Group, Inc. was founded in 2017 and is based in Scottsdale, Arizona. |
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Gouk Warren | Chief Administrative Officer | Aug 23 | Sale | 7.02 | 17,226 | 120,927 | 6,144,748 | Aug 24 05:15 PM | | Gouk Warren | Chief Administrative Officer | Aug 15 | Sale | 7.85 | 17,226 | 135,224 | 6,161,974 | Aug 16 04:00 PM | | Gouk Warren | Chief Administrative Officer | Aug 08 | Sale | 7.30 | 17,226 | 125,750 | 6,179,200 | Aug 10 05:00 PM | | Gouk Warren | Chief Administrative Officer | Aug 03 | Sale | 7.00 | 68,904 | 482,328 | 6,196,426 | Aug 05 04:15 PM | | Lester Michael K. | President and CEO | Jun 13 | Sale | 5.33 | 328,615 | 1,751,518 | 23,148,931 | Jun 14 04:40 PM |
|
|
| |
 |
| Market Cap | 1.11B | EPS (ttm) | -1.64 |
| P/E | - | EPS this Y | -639.00% |
| Forward P/E | - | EPS next Y | - |
| PEG | - | EPS past 5Y | - |
| P/S | 9.57 | EPS next 5Y | - |
| P/B | - | EPS Q/Q | - |
| Dividend | - | Sales Q/Q | 137.00% |
| Insider Own | - | Inst Own | 98.30% |
| Insider Trans | - | Inst Trans | - |
| Short Float | 0.09% | Earnings | Aug 22/b |
| Analyst Recom | 2.20 | Target Price | 12.25 |
| Avg Volume | 343.98K | 52W Range | 3.35 - 28.44 |
|
|
| Sep-08-22 | Initiated |
Citigroup |
Buy |
$10 |
|
|
|
|
| Allego N.V. operates as an electric vehicle (EV) charging company. The company offers charging solutions for electric cars, motors, buses, and trucks. It has a charging network with renewable energy and charging solutions for business-to-business customers, including leading retail and auto brands. The company has approximately 28,000 charging ports in Europe. It also provides Allego EV Cloud, a customer payment tool that offers essential services to owned and third-party customers comprising authorization and billing, smart charging and load balancing, analysis, and customer support. The company was founded in 2013 and is based in Arnhem, the Netherlands. |
|
|
 |
| Market Cap | 2.23B | EPS (ttm) | -0.14 |
| P/E | - | EPS this Y | 68.20% |
| Forward P/E | - | EPS next Y | - |
| PEG | - | EPS past 5Y | 42.20% |
| P/S | 15.01 | EPS next 5Y | - |
| P/B | 3.91 | EPS Q/Q | 56.10% |
| Dividend | - | Sales Q/Q | 994.30% |
| Insider Own | 89.10% | Inst Own | 1.10% |
| Insider Trans | 0.00% | Inst Trans | - |
| Short Float | 0.90% | Earnings | - |
| Analyst Recom | - | Target Price | - |
| Avg Volume | 1.28M | 52W Range | 2.36 - 52.80 |
|
|
|
|
| Nutex Health, Inc. operates as a technology-enabled healthcare services company. It operates through two divisions: Hospital division and Population Health Management division. The Hospital division implements and operates health care models, including micro-hospitals, specialty hospitals, and hospital outpatient departments. This division owns and operates 21 facilities in 8 states. The Population Health Management division owns and operates provider networks, such as independent physician associations. Its management services organizations provide management, administrative, and other support services to its affiliated hospitals and physician groups. This division's cloud-based proprietary technology platform aggregates data across multiple information systems, settings, and sources to create a holistic view of each patient and provider, as well as allows to deliver care. The company is based in Houston, Texas. |
|
| |
 |
| Market Cap | 2.23B | EPS (ttm) | -0.17 |
| P/E | - | EPS this Y | -117.70% |
| Forward P/E | 41.18 | EPS next Y | 41.18% |
| PEG | - | EPS past 5Y | -17.30% |
| P/S | 5.01 | EPS next 5Y | 18.20% |
| P/B | 3.61 | EPS Q/Q | -33.60% |
| Dividend | - | Sales Q/Q | -2.50% |
| Insider Own | 1.00% | Inst Own | 87.70% |
| Insider Trans | -4.30% | Inst Trans | 1.32% |
| Short Float | 3.72% | Earnings | Sep 07/a |
| Analyst Recom | 2.20 | Target Price | 96.33 |
| Avg Volume | 244.73K | 52W Range | 52.03 - 114.11 |
|
|
|
|
| AeroVironment, Inc. designs, develops, produces, delivers, and supports a portfolio of robotic systems and related services for government agencies and businesses in the United States and internationally. It operates through four segments: Unmanned Aircraft Systems (UAS), Tactical Missile System (TMS), Medium Unmanned Aircraft Systems (MUAS), and High Altitude Pseudo-Satellite Systems (HAPS). The company supplies UAS, TMS, unmanned ground vehicle, and related services primarily to organizations within the U.S. Department of Defense and to international allied governments. It also designs, engineers, tools, and manufactures unmanned aerial and aircraft systems, including airborne platforms, payloads and payload integration, ground control systems, and ground support equipment and other items and services related to unmanned aircraft systems. In addition, the company offers small UAS products, including spare equipment, alternative payload modules, batteries, chargers, repair services, and customer support, as well as multiple aircraft, hand-held ground control system, and spare parts and accessories. Further, it develops high-altitude pseudo-satellite UAS systems. The company was incorporated in 1971 and is headquartered in Arlington, Virginia. |
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Holland Charles R | Director | Jul 07 | Sale | 84.20 | 4,001 | 336,884 | 56,998 | Jul 11 04:27 PM | | Holland Charles R | Director | Jul 06 | Sale | 82.61 | 2,001 | 165,303 | 60,999 | Jul 06 07:51 PM | | Holland Charles R | Director | Jul 05 | Sale | 80.87 | 3,001 | 242,691 | 63,000 | Jul 06 07:51 PM | | Nawabi Wahid | President and CEO | Jun 29 | Option Exercise | 0.00 | 6,695 | 0 | 75,764 | Jul 01 05:49 PM | | Brown Melissa Ann | VP, Gen. Counsel, Corp. Sec | Jun 29 | Option Exercise | 0.00 | 984 | 0 | 12,321 | Jul 01 05:50 PM |
|
|
|
 |
| Market Cap | 1.06B | EPS (ttm) | -3.49 |
| P/E | - | EPS this Y | 53.80% |
| Forward P/E | - | EPS next Y | 7.40% |
| PEG | - | EPS past 5Y | -4.40% |
| P/S | 79.39 | EPS next 5Y | -9.00% |
| P/B | 5.38 | EPS Q/Q | -26.70% |
| Dividend | - | Sales Q/Q | 4180.00% |
| Insider Own | 0.10% | Inst Own | 93.60% |
| Insider Trans | -31.05% | Inst Trans | -5.63% |
| Short Float | 15.68% | Earnings | Aug 02/b |
| Analyst Recom | 2.10 | Target Price | 29.67 |
| Avg Volume | 2.52M | 52W Range | 3.04 - 27.29 |
|
|
|
|
| Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alstrom syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. Rhythm Pharmaceuticals, Inc. has a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts. |
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Cramer Pamela J. | Chief Human Resources Officer | Aug 19 | Option Exercise | 19.02 | 13,493 | 256,637 | 15,717 | Aug 23 04:30 PM | | Cramer Pamela J. | Chief Human Resources Officer | Aug 19 | Sale | 24.83 | 13,493 | 335,031 | 2,224 | Aug 23 04:30 PM | | Cramer Pamela J. | Chief Human Resources Officer | Jul 27 | Sale | 11.68 | 901 | 10,524 | 2,224 | Jul 28 04:31 PM | | Smith Hunter C | Chief Financial Officer | Jul 01 | Sale | 4.08 | 7,547 | 30,792 | 57,614 | Jul 06 06:08 PM | | Roberts William T. | Chief Accounting Officer | Mar 29 | Sale | 11.13 | 1,023 | 11,386 | 1,477 | Mar 31 04:31 PM |
|
|
|
 |
| Market Cap | 80.01M | EPS (ttm) | -0.38 |
| P/E | - | EPS this Y | 49.70% |
| Forward P/E | 38.83 | EPS next Y | 328.60% |
| PEG | - | EPS past 5Y | 32.50% |
| P/S | 4.94 | EPS next 5Y | 20.00% |
| P/B | 7.91 | EPS Q/Q | 76.50% |
| Dividend | - | Sales Q/Q | 55.20% |
| Insider Own | 2.40% | Inst Own | 21.00% |
| Insider Trans | -9.70% | Inst Trans | 0.15% |
| Short Float | 3.29% | Earnings | Aug 16/a |
| Analyst Recom | 1.70 | Target Price | 11.00 |
| Avg Volume | 67.85K | 52W Range | 4.25 - 9.21 |
|
|
|
|
| QuickLogic Corporation, a semiconductor company, develops semiconductor platforms and intellectual property solutions for smartphones, wearable, hearable, tablets, and the Internet-of-Things devices. It also provides flexible sensor processing solutions, ultra-low power display bridges, ultra-low power field programmable gate arrays (FPGAs); and analytics toolkit, an end-to-end software suite that offers processes for developing pattern matching sensor algorithms using machine learning technology, as well as programming hardware and design software solutions. The company's products include pASIC 3, QuickRAM, QuickPCI, EOS, QuickAI, SensiML Analytics Studio, ArcticLink III, PolarPro 3, PolarPro II, PolarPro, and Eclipse II, as well as silicon platforms, IP cores, software drivers, firmware, and application software. It delivers its solutions through ultra-low power customer programmable System on Chip (SoC) semiconductor solutions, embedded software, and algorithm solutions for always-on voice and sensor processing, and enhanced visual experiences. In addition, the company licenses FPGA technology for use in other semiconductor companies SoCs. It markets and sells its products to original equipment manufacturers and original design manufacturers through a network of sales managers and distributors in North America, Europe, and the Asia Pacific. QuickLogic Corporation was founded in 1988 and is headquartered in San Jose, California. |
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Nader Elias | CFO, SVP FINANCE | Aug 15 | Sale | 8.26 | 1,876 | 15,496 | 2,673 | Aug 16 12:02 PM | | Nader Elias | CFO, SVP FINANCE | Aug 10 | Option Exercise | 0.00 | 2,804 | 0 | 4,549 | Aug 11 03:56 PM | | Faith Brian C | PRESIDENT AND CEO | Jul 26 | Sale | 7.71 | 16,395 | 126,478 | 135,339 | Jul 27 01:02 PM | | SAXE TIMOTHY | SR. VP AND CTO | Jul 15 | Option Exercise | 0.00 | 21,331 | 0 | 92,947 | Jul 19 04:40 PM | | TAUSS GARY H | Director | Jul 15 | Option Exercise | 0.00 | 3,716 | 0 | 14,315 | Jul 19 04:39 PM |
|
|
|
|
12345678910next
|
|
|
